Eupraxia Pharmaceuticals Inc. (EPRX)
NASDAQ: EPRX · IEX Real-Time Price · USD
2.730
+0.060 (2.25%)
Jul 22, 2024, 10:38 AM EDT - Market open
Eupraxia Pharmaceuticals Employees
Eupraxia Pharmaceuticals had 29 employees as of December 31, 2023. The number of employees increased by 8 or 38.10% compared to the previous year.
Employees
29
Change (1Y)
8
Growth (1Y)
38.10%
Revenue / Employee
n/a
Profits / Employee
n/a
Market Cap
93.33M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 29 | 8 | 38.10% |
Dec 31, 2022 | 21 | 0 | - |
Dec 31, 2021 | 21 | 9 | 75.00% |
Dec 31, 2019 | 12 | 0 | - |
Dec 31, 2018 | 12 | - | - |
Related Stocks
Company Name | Employees |
---|---|
111, Inc. | 1,520 |
LakeShore Biopharma | 773 |
Asensus Surgical | 209 |
Aclaris Therapeutics | 91 |
Assembly Biosciences | 65 |
InflaRx | 62 |
BeyondSpring | 36 |
Eton Pharmaceuticals | 30 |
EPRX News
- 14 days ago - Eupraxia Pharmaceuticals to Present at Controlled Release Society 2024 Annual Meeting and Expo - PRNewsWire
- 18 days ago - Eupraxia Pharmaceuticals' CEO Dr. James Helliwell to Participate in Webinar Event, "Exploring the Rapid Rise of Osteoarthritis" on July 9, 2024 - PRNewsWire
- 6 weeks ago - Eupraxia Pharmaceuticals Announces Voting Results from Annual General and Special Meeting of Shareholders - PRNewsWire
- 6 weeks ago - Eupraxia Pharmaceuticals to Present Data from the Phase 2 SPRINGBOARD Study in Osteoarthritis of the Knee at EULAR European Congress of Rheumatology 2024 - PRNewsWire
- 2 months ago - Eupraxia Pharmaceuticals Announces Expansion of RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis - PRNewsWire
- 2 months ago - Eupraxia Pharmaceuticals to Host Virtual KOL Event on EP-104GI Clinical Development Program for Eosinophilic Esophagitis ("EoE") on May 29, 2024 - PRNewsWire
- 2 months ago - Eupraxia Pharmaceuticals Announces New Positive Data from RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis - PRNewsWire
- 2 months ago - Eupraxia Pharmaceuticals to Present Initial Results from Ongoing Phase 1b Study of EP-104GI for the Treatment of Eosinophilic Esophagitis at Upcoming Digestive Disease Week Annual Meeting 2024 - PRNewsWire